Traws Pharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 |
| Operating income | -$17.9M | -$142.4M | -$20.3M | -$19.6M | -$16.5M |
| Operating expenses | $20.7M | $142.6M | $20.5M | $19.9M | $16.7M |
| Cash from operations | -$18.2M | -$29.8M | -$17.9M | -$16.3M | -$19.5M |
| Capital expenditure | $2.6M | $3.6M | $14,000 | — | — |
| Free cash flow | -$20.8M | -$33.4M | -$17.9M | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $10.6M | $25.0M | $22.7M | $39.4M | $55.5M |
| Total liabilities | $11.2M | $56.6M | $12.0M | $11.1M | $9.4M |
Shares outstanding 15.2M · Free float 6.4%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.